Exenatide
Also called Byetta, Bydureon, Exendin-4
Subcutaneous (under the skin)Product label
Research reference
Product label
Byetta immediate-release pen
5 mcg before each of two main meals, at least 6 hours apart; 10 mcg may be considered after one month
One calendar month before a possible increase—not a four-week automatic change
Byetta label (2025), sections 2 and 5 ↗When results may show
- When change was measured
- Glucose response and tolerability guide review. Meal timing matters; a fixed every-12-hours reminder is not the label schedule.
- When to assess
- One calendar month before a possible increase—not a four-week automatic change
- Conditions and limitations
- Adults with type 2 diabetes; exact Byetta product. Do not copy to once-weekly extended-release exenatide or an unidentified powder vial. Kidney function and the full label matter.
- When to stop
- Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Key properties
- Formula
- C184H282N50O60S
- Mol. weight
- 4,186.63 Da
- CAS
- 141758-74-9
- PubChem CID
- 16157882
External references
Vial arithmetic
Published research contexts for Exenatide describe 5–10 mcg per administration. Descriptive only, not a recommendation.
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.03× single dose
- Time to steady state
- 12hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Byetta label (2025), sections 2 and 5Do not copy to once-weekly extended-release exenatide or an unidentified powder vial. Kidney function and the full label matter.
Next steps
Exenatide beginner guideOpen Exenatide planning worksheetEstimate Exenatide vial costTrack Exenatide notes